The Latin America pharmaceutical contract manufacturing and research services market size stood at US$ 22.53 billion in 2025, grew to US$ 24.09 billion in 2026, and is forecast to reach US$ 43.99 billion by 2035, expanding at a CAGR of 6.92% from 2026 to 2035.
Pharmaceutical contract manufacturing is the procedure where a pharmaceutical organization outsources the manufacturing of medicines to specialised third-party manufacturers. The pharmaceutical sector is continuously under pressure to produce efficient and inexpensive medicines. With increasing worldwide demand, companies require reliable partners who produce massive quantities of medicines without compromising on quality. It provides a unique integration of skilled labour, progressive infrastructure, and inexpensive pricing. A contract manufacturing organization (CMO) emphasizes mainly the manufacturing of drugs based on the customer's formulation. They ensure that the production processes are smooth, effective, and compliant with government standards. Outsourcing reduces financial challenges and accelerates time by leveraging specialized equipment and expertise.
Pharmaceutical contract manufacturing is a service whereby a third party assembles and produces, or partially produces, pharmaceutical products according to the expectations of its client. Pharmaceutical contract manufacturing offers cost savings, access to specialized services, increased productivity, and improved quality control. Key drivers in the Latin America pharmaceutical contract manufacturing and research services market include rising demand for affordable generics, cost-effective operations, and improved regulatory frameworks. Future opportunities stem from nearshoring, expanding clinical trial capabilities, and local manufacturing for biosimilars and biologics.
AI-driven technology rapidly analyzes significant biological and chemical datasets, significantly shrinking the time required to detect therapeutic targets and hopeful drug candidates. AI-based technology in pharmaceutical products delivers measurable advantages, quality enhancements, and cost savings. This technology contributes to lowering development costs by optimizing research and development technology. It enhances effectiveness and lowers expenses by automating repetitive tasks like data processing, production monitoring, and documentation. AI-driven technology serves as a significant tool that helps industry experts to be more well-organized and productive. AI-based technology contributes to lowering development expenses by enhancing research and development processes. Machine learning algorithms assist in experimental design. It enhances effectiveness and lowers costs by automating repetitive tasks like data processing, industrial monitoring, and documentation.
Smart Manufacturing
Smart manufacturing is transforming the Latin America pharmaceutical contract manufacturing and research services market by enabling pharmaceutical companies to adopt flexible, data-driven, and highly automated production processes. Advanced technologies such as artificial intelligence, machine learning, robotics, and real-time analytics improve operational efficiency, reduce production errors, and accelerate time-to-market. These capabilities help contract manufacturers respond quickly to changing drug demand, regulatory requirements, and complex therapeutic development needs while ensuring consistent product quality and cost optimization.
Personalized Medicine
Personalized medicine is emerging as a major growth trend in the Latin America market. Increasing demand for targeted therapies, precision drugs, and patient-specific treatment approaches is encouraging pharmaceutical companies to collaborate with specialized contract manufacturers and research organizations. These services support biomarker discovery, clinical research, and customized production processes. Personalized medicine enhances treatment effectiveness, improves patient outcomes, reduces adverse reactions, and promotes greater patient engagement, driving innovation across healthcare systems.
Biologics
The growing focus on biologics is significantly influencing the Latin America pharmaceutical contract manufacturing and research services market. Rising demand for monoclonal antibodies, biosimilars, vaccines, and advanced biologic therapies is encouraging investments in specialized manufacturing capabilities and research infrastructure. Contract service providers are adopting efficient and sustainable production practices that reduce resource consumption and operational costs while maintaining regulatory compliance. These advancements enhance manufacturing productivity, product quality, and scalability, enabling pharmaceutical companies to meet expanding global and regional healthcare demands.
| Table | Scope |
| Market Size in 2026 | USD 24.09 Billion |
| Projected Market Size in 2035 | USD 43.99 Billion |
| CAGR (2026 - 2035) | 6.92% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Service Type, By Product Type, By Therapeutic Area, By End User, By Region |
| Top Key Players | Eurofarma Laboratórios S.A., Laboratorios Liomont S.A. de C.V., Libbs Farmacêutica, Blau Farmacêutica S.A., PiSA Farmacéutica |
| Segment | Share 2025 (%) |
| Contract Manufacturing Services (CMO) | 65% |
| Contract Research Services (CRO) | 35% |
The Contract Manufacturing Services (CMO) Segment Led the Market in 2025
The contract manufacturing services (CMO) segment contributed the largest Latin America pharmaceutical contract manufacturing and research services market share of 65% in 2025, as contract manufacturing is that it modernizes manufacturing, leading to affordability and lowering challenges. Contract manufacturing provides a wide range of advantages, from affordability and increased operational effectiveness to access to targeted expertise. Contract manufacturing enables companies to tap into cost savings by leveraging the proficiency and economies of scale of industrial partners.
The contract research services (CRO) segment held a significant share of 35% and is expected to grow at the fastest CAGR of 7.80% during the forecast period, in the market, as CROs accelerate timelines because of established processes and worldwide networks. It offers hands-on site support, ensuring that the research sites are well-organized and that the trial preserves the highest standards of quality and protocol adherence.
| Segment | Share 2025 (%) |
| Small Molecule Drugs | 58% |
| Biologics | 30% |
| Biosimilars | 12% |
Small Molecule Drugs Segment Led the Market in 2025
The small molecule drugs segment contributed the largest Latin America pharmaceutical contract manufacturing and research services market share of 58%. Small molecule drugs provide numerous benefits, starting with their increasing oral bioavailability, which enables convenient self-administration, most often in oral solid dose (OSD) form. Small molecule drugs such as penicillin for managing bacterial infections, aspirin for pain relief and inflammation, and statins for managing cholesterol.
The biologics segment held a significant share of 30% of the market and is expected to grow at the fastest CAGR of 8.50% during the forecast period. Biologics enable pharmaceutical organizations to grow more intentionally, as they meet manufacturing deadlines and increased demand by adjusting manufacturing quantity as required, simply by adding a drug variation.
The biosimilars segment held a significant share of 12% of the market as biosimilar drugs involve lowered healthcare expenses, growing access to management, and stimulating competitive assessment. Biosimilars provide contract manufacturing organizations (CMOs) with strategic benefits by reducing development challenges, increasing the application of specialized facilities, and increasing worldwide market access.
| Segment | Share 2025 (%) |
| Oncology | 28% |
| Infectious Diseases | 16% |
| Cardiovascular Diseases | 14% |
| Neurology | 10% |
| Metabolic Disorders | 12% |
| Respiratory Diseases | 7% |
| Immunology | 8% |
| Rare Diseases | 3% |
| Others | 2% |
The Oncology Segment led the Market in 2025
The oncology segment held a significant share of 28% in the Latin America pharmaceutical contract manufacturing and research services market and is expected to grow at the fastest CAGR of 8.70% during the forecast period. Contract manufacturing involves access to specialised oncology services, earlier time-to-market, expense optimisation, regulatory compliance support, and scalable manufacturing capacity. CROs avoid the increasing expenses of building, maintaining, and upgrading production facilities.
The infectious diseases segment contributed to a market share of 16%, as pharmaceutical contract manufacturing offers affordability, flexibility, and scalability. Integrated continuous biomanufacturing technology is rapid and cheaper, and provides more consistent processing and advanced product quality. CDMOs allow organisations to ramp up manufacturing volumes exponentially through an unexpected outbreak.
The cardiovascular diseases segment held a significant 14% share of the Latin America pharmaceutical contract manufacturing and research services market, as contract manufacturers support the development of high-performance cardiovascular products. Contract manufacturing offers medical care enterprises access to advanced tools, skilled staff, product testing, quality checking, and maintenance activities at dramatically lowered costs.
The neurology segment held a significant share of 10% in the market, as pharmaceutical contract manufacturing supports neurology services to meet the progressively complex demands of the manufacturing. It is an affordable way to outsource the production of pharmaceutical products, medical tools, and components.
| Segment | Share 2025 (%) |
| Pharmaceutical Companies | 48% |
| Biotechnology Companies | 24% |
| Generic Drug Manufacturers | 16% |
| Academic & Research Institutes | 7% |
| Government Organizations | 5% |
The Pharmaceutical Companies Segment led the Market in 2025
The pharmaceutical companies segment contributed the largest Latin America pharmaceutical contract manufacturing and research services market share of 48%, as pharmaceutical contract manufacturing offers affordability, flexibility, and scalability. These companies save millions by avoiding the maintenance, construction, and upgrading of physical production facilities. Contract production already has the supply chain and manufacturing lines set up; organizations bring novel medications.
The biotechnology companies segment held a significant share of 24% in the market and is expected to grow at the fastest CAGR of 8.90% during the forecast period. These companies significantly lower operational expenses, like those related to targeted personnel, device maintenance and upgrades, and capability management. This affordability often translates into lower manufacturing expenses and enhanced profit margins.
The generic drug manufacturers segment held a significant share of 16% in the Latin America pharmaceutical contract manufacturing and research services market, as generic drugs generally cost 30-80% less than their patented equivalents, creating important treatments accessible to a wider population. Generic drugs provide many advantages, such as enhanced bioavailability, increased efficacy and safety, and reduced adverse effects.
The academic & research institutes segment held a significant share of 7% in the market, as these research institutes improve the standing of universities. Attracts top-notch students and instructors. Society benefits from the reactions to significant challenges and developments that enhance patients’ quality of life, achieved via research.
The global pharmaceutical contract manufacturing and research services market size was estimated at USD 281.68 billion in 2025 and is predicted to increase from USD 301.23 billion in 2026 to approximately USD 551.01 billion by 2035, expanding at a CAGR of 6.94% from 2026 to 2035.
The Latin America pharmaceutical contract manufacturing and research services market is growing rapidly due to rising pharmaceutical production, increasing clinical research activities, and expanding demand for cost-effective outsourcing solutions. Growing investments in biologics, biosimilars, and advanced manufacturing technologies are further supporting market expansion. Additionally, favorable regulatory developments, skilled workforce availability, and increasing partnerships between global pharmaceutical companies and regional service providers continue to drive growth.
Brazil Market Trends
Brazil contributed the largest market share of 40% and is expected to grow at the fastest CAGR of 7.20% during the forecast period, as this region hosts an important number of GMP-certified production plants. Brazilian contract manufacturers offer foreign companies, specifically in pharmaceuticals and consumer products, significant market entry and lower initial capital expenses.
Mexico Market Trends
Mexico held a significant share of 22% in the Latin America pharmaceutical contract manufacturing and research services market, featuring specialized manufacturing hubs where complete supply chains are concentrated. Mexico's manufacturing is the keystone of North America’s nearshoring revolt, providing an important combination of cost savings, proximity, and sophistication for companies moving away from various offshore manufacturing locations.
Argentina Market Trends
Argentina held a significant share of 12% in the market, as this region's healthcare production sector is in the midst of a clear recession. Argentina has one of Latin America's most active domestic biosimilar progressive sectors, with major key players such as mAbxience. Argentina works to build its production base, and spending on the production of abundant, cost-effective natural gas is important to creating advanced healthcare production.
| Company | Headquarters | Latest Update |
| Eurofarma Laboratórios S.A. | Brazil | These manufacturing activities in Pfizer's and BioNTech's global COVID-19 vaccine supply chain and manufacturing network. |
| Laboratorios Liomont S.A. de C.V. | Mexico | Laboratorios Liomont is a pharmaceutical manufacturing, drug manufacturing, and research, and pharmaceutical company located in MX with $31.6 million. |
| Libbs Farmacêutica | Brazil | Libbs Farmacêutica will have a high-class license for the commercialization, marketing, and distribution of the biosimilar in Brazil. |
| Blau Farmacêutica S.A | Brazil | Blau Farmaceutica SA is involved in the production, development, and commercialization of challenging private-label drugs for the institutional market. |
| PiSA Farmacéutica | Mexico | Adium Pharma reaches an imperative agreement with Moderna Inc. to cooperate in the distribution and commercialization of covid 19 vaccines in Latin America. |
In May 2026, “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well-positioned to bring this important therapy to patients living with autoimmune diseases. Together, we aim to improve access to effective and affordable treatment options across the region.”
By Service Type
By Product Type
By Therapeutic Area
By End User
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
